Third-Quarter Net Revenue of $3.5 Million;

Operational Improvements Result In First Profitable Quarter

SOUTH ORANGE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2024.

Financial Highlights*

Net income of $0.2 million, compared to a net loss of $0.2 million
Adjusted EBITDA of $295,000, compared to $11,000
Net revenue of $3.5 million, an 8% increase over Q2 2024; a decrease of 6% over Q3 prior year

*Stated performance is relative to same period in the prior year unless otherwise noted.

"I am very excited to report our first profitable quarter, marking a major milestone in our pursuit of achieving operational excellence. I am also pleased to report we had positive-adjusted EBITDA for both the third quarter and first nine months of 2024," stated Robert Banks, President and Chief Executive Officer. "Although most of our sales regions showed solid growth and steady performance with existing customers, our [South Central] region continued to miss expectations, which resulted in some reorganization. Additionally, a handful of our larger accounts exhibited slower-than-usual ordering patterns, as demonstrated by a slight decrease in same-site sales. We continue to push forward with actions designed to mitigate the reduction in programmatic reorders, as outlined during our previous earnings call."

Mr. Banks continued, "While Nephros prepares to launch digital support for filter installation, we are ramping up our service capabilities to foster installation commissions and complement filter sales. We believe these efforts will offset customer non-compliance with filter changeout schedules."

Financial Performance for the Quarter Ended September 30, 2024

Net revenue for the quarter ended September 30, 2024, was $3.5 million, compared to $3.7 million in the corresponding period in 2023, a decrease of 6%. The third quarter of 2023 was one of our largest quarters by revenue ever, with several new accounts placing initial orders of significant size. Although those 2023 customers have continued to order, their 2024 replacement orders have been smaller by comparison. Another contributing factor to our decreased quarterly revenue was underperformance across our South Central region, despite an 8% increase from our prior quarter.

Cost of goods sold for the quarter ended September 30, 2024, was $1.4 million, compared with $1.5 million for the quarter ended September 30, 2023, a decrease of 12%. Gross margins for the quarter ended September 30, 2024, were 61% compared to 59% for the quarter ended September 30, 2023, reflecting improved terms with our largest supplier.

Research and development expenses for each of the quarters ended September 30, 2024, and September 30, 2023, were $0.2 million. Depreciation and amortization expense for the quarter ended September 30, 2024, was approximately $34,000, compared with approximately $55,000 for the corresponding period in 2023.

Selling, general and administrative expenses for the quarter ended September 30, 2024, was $1.7 million compared to $2.1 million during the same period in 2023 due to a decline in stock compensation and bonus accruals.

Net income for the quarter ended September 30, 2024, was $0.2 million, compared to a net loss of $0.2 million during the same period in 2023. The decrease in net loss was driven by decreased operating expenses reflecting a reduction in bonus accrual and stock compensation expense. Additionally, we continue our intense focus on managing expenses and working toward improving efficiency with the aim of providing our unique products and services in a more streamlined manner.

Adjusted EBITDA for the quarter ended September 30, 2024, was $295,000, compared to $11,000 during the same period in 2023 reflecting primarily our operating profit for the quarter.

As of September 30, 2024, Nephros had cash and cash equivalents of $2.5 million, compared to $4.3 million as of December 31, 2023. The decline in cash from year-end 2023 was driven primarily by the operating loss for the first half of 2024, as well as payment of annual employee bonuses and an investment in inventory in the first quarter of 2024.

Adjusted EBITDA Definition and Reconciliation to GAAP Financial Measures

Adjusted EBITDA is calculated by taking net loss calculated in accordance with generally accepted accounting principles ("GAAP") and excluding all interest-related expenses and income, tax-related expenses and income, non-recurring expenses and income, and non-cash items, including depreciation, amortization, non-cash inventory write-offs, and non-cash compensation. The following tables present a reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP financial measure, for the third quarter and year to date of the 2024 and 2023 fiscal years:

(unaudited)

	Three Months Ended September 30,
Consolidated Results	2024		2023
	(in $ thousands)
Reconciliation of net income (loss):
Net Income (loss)	183		(182	)

Adjustments:
Depreciation of property and equipment	12		9
Amortization of other assets	21		46
Interest income	(20	)	(11	)
Non-cash stock-based compensation	65		149
Non-cash inventory write-offs	34		-

Adjusted EBITDA Income	295		11



(unaudited)

	Nine Months Ended September 30,
Consolidated Results	2024		2023
	(in $ thousands)
Reconciliation of net loss:
Net Income (loss)	(275	)	(921	)

Adjustments:
Depreciation of property and equipment	34		29
Amortization of other assets	68		134
Interest expense	1		1
Interest income	(66	)	(36	)
Non-cash stock-based compensation	91		662
Non-cash inventory write-offs	214		106

Adjusted EBITDA Income (loss)	67		(25	)

Nephros believes that Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to Nephros' financial condition and results of operations. Management does not consider Adjusted EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be recognized in Nephros' financial statements. In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgments by management about which expenses and income are excluded or included in determining Adjusted EBITDA. To compensate for these limitations, management presents Adjusted EBITDA in connection with net income loss, the most directly comparable GAAP financial measure. Nephros urges investors to review the reconciliation of Adjusted EBITDA to net income loss and not to rely on any single financial measure to evaluate the business.

Conference Call Today at 4:30pm ET

Nephros will host a conference call today at 4:30pm ET, during which management will discuss Nephros' financial results and provide a general business overview.

Participants may dial into the call as follows:

Domestic access: 1 (844) 808-7106

International access: 1 (412) 317-5285

Upon joining, please ask to be added into the Nephros conference call.

An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.

Alternatively, a replay of the call may be accessed until November 14, 2024 at 1 (877) 344-7529 or 1 (412) 317-0088 for international callers and entering replay access code: 5018166.

About Nephros

Nephros is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the needs of customers within medical and commercial markets, offering both proactive and emergency solutions for water management.

For more information about Nephros, please visit nephros.com.

Forward-Looking Statements

This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros' expected future revenue, gross margins, cash flows and expectations on maintaining positive cash flow and profitability, and other future financial performance, the expected timing of the launch of new products and services, expected improvements in efficiency in the delivery of our products and services, and other statements that are not historical facts, including statements that may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including inflationary factors and general economic conditions, changes in business and competitive conditions, fluctuations in customer order volumes, unpredictability with respect to revenue derived from emergency response orders, the availability of capital when needed, dependence on third-party manufacturers and researchers, and regulatory reforms. These and other risks and uncertainties are detailed in Nephros' reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2023, which it may update in Part II, Item 1A – Risk Factors in its Quarterly Reports on Form 10-Q that it has filed or will file hereafter. Nephros does not undertake any responsibility to update the forward-looking statements in this release.

Investor Relations Contacts:

Kirin Smith, President Robert Banks, CEO

PCG Advisory, Inc.

(646) 823-8656

ksmith@pcgadvisory.com

Robert Banks, CEO

Nephros, Inc.

(201)343-5202x121

robert.banks@nephros.com

NEPHROS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
		2024			2023			2024			2023
Net revenue:
Product revenues	$	3,472		$	3,713		$	10,186		$	10,912
Royalty and other revenues		46			29			106			72
Total net revenues		3,518			3,742			10,292			10,984
Cost of goods sold		1,369			1,548			4,044			4,600
Gross margin		2,149			2,194			6,248			6,384
Operating expenses:
Selling, general and administrative		1,721			2,137			5,804			6,500
Research and development		188			205			654			665
Depreciation and amortization		34			55			101			163
Total operating expenses		1,943			2,397			6,559			7,328
Operating income (loss)		206			(203	)		(311	)		(944	)
Other (expense) income:
Interest expense		-			-			(1	)		(1	)
Interest income		20			11			66			36
Other income (expense), net		(43	)		10			(29	)		(12	)
Total other expense:		(23	)		21			36			23
Net income (loss)	$	183		$	(182	)	$	(275	)	$	(921	)


Net income (loss) per common share, basic	$	0.02		$	(0.02	)	$	(0.03	)	$	(0.09	)
Net income (loss) per common share, diluted	$	0.02		$	(0.02	)	$	(0.03	)	$	(0.09	)

Weighted average common shares outstanding, basic		10,544,139			10,460,866			10,518,742			10,352,108
Weighted average common shares outstanding, diluted		10,580,906			10,460,866			10,518,742			10,352,108

NEPHROS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)

ASSETS	September 30, 2024			December 31, 2023
Current assets:
Cash and cash equivalents	$	2,457		$	4,307
Accounts receivable, net		1,691			1,496
Inventory		3,099			2,470
Prepaid expenses and other current assets		109			132
Total current assets		7,356			8,405
Property and equipment, net		173			152
Lease right-use-of assets		1,461			1,807
Intangible assets, net		357			381
Goodwill		759			759
License and supply agreement, net		230			271
Other assets		50			86
TOTAL ASSETS	$	10,386		$	11,861

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable		398			873
Accrued expenses		322			794
Current portion of lease liabilities		338			446
Total current liabilities		1,058			2,113
Lease liabilities, net of current portion		1,154			1,390
TOTAL LIABILITIES		2,212			3,503

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY:
Preferred stock, $.001 par value; 5,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding September 30, 2024 and December 31, 2023.		-			-
Common stock, $.001 par value; 40,000,000 shares authorized at September 30, 2024 and December 31, 2023; 10,544,139 and 10,543,675 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively.		11			10
Additional paid-in capital		152,844			152,754
Accumulated deficit		(144,681	)		(144,406	)
TOTAL STOCKHOLDERS' EQUITY		8,174			8,358
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	10,386		$	11,861

Nephros Announces Financial Results for Quarter Ended September 30, 2024